62,970 Shares in Assembly Biosciences, Inc. (NASDAQ:ASMB) Purchased by Peapod Lane Capital LLC

Peapod Lane Capital LLC bought a new stake in Assembly Biosciences, Inc. (NASDAQ:ASMB) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 62,970 shares of the biopharmaceutical company’s stock, valued at approximately $994,000. Peapod Lane Capital LLC owned about 0.99% of Assembly Biosciences at the end of the most recent quarter.

Separately, FMR LLC increased its stake in Assembly Biosciences by 29.7% in the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock valued at $240,000 after purchasing an additional 3,635 shares during the last quarter. 19.92% of the stock is owned by institutional investors and hedge funds.

Assembly Biosciences Stock Performance

Shares of ASMB opened at $12.57 on Thursday. Assembly Biosciences, Inc. has a 12 month low of $11.01 and a 12 month high of $19.93. The stock’s 50-day moving average is $15.12 and its two-hundred day moving average is $15.68.

Insider Buying and Selling at Assembly Biosciences

In related news, Director Michael Houghton acquired 3,202 shares of the firm’s stock in a transaction on Monday, December 30th. The stock was bought at an average cost of $15.61 per share, with a total value of $49,983.22. Following the acquisition, the director now directly owns 3,202 shares in the company, valued at approximately $49,983.22. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 5.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Assembly Biosciences in a research note on Friday, December 27th.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.